Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has earned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $44.25.

Several brokerages recently commented on DMRA. Weiss Ratings restated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Guggenheim reiterated a “buy” rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Zacks Research raised Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. Wall Street Zen upgraded Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Lifesci Capital raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, February 2nd.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $40,000. Geode Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $266,000. Virtu Financial LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $49,000. Sigma Planning Corp acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $334,000. Finally, Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $76,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Price Performance

DMRA stock opened at $25.09 on Friday. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -2.07 and a beta of 1.59. The company’s fifty day simple moving average is $26.80 and its 200 day simple moving average is $20.55. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.01 and a 12-month high of $38.33.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.